916489-36-6

Usage

Uses

Used in Oncology:
MS417 is used as an anticancer agent for its ability to inhibit PARP enzymes, which are essential for DNA repair in cancer cells. By targeting this mechanism, MS417 disrupts the cancer cells' capacity to repair DNA damage, resulting in their destruction. This makes it a promising treatment option for various types of cancer.
Used in Neuroprotection:
MS417 is used as a neuroprotective agent due to its demonstrated ability to protect neurons from damage and degeneration. This property makes it a potential candidate for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's, where neuronal protection is crucial for slowing disease progression.
Used in Anti-inflammatory Applications:
MS417 is used as an anti-inflammatory agent, leveraging its capacity to reduce inflammation and associated tissue damage. This application makes it a potential therapeutic option for conditions characterized by chronic inflammation, such as arthritis and autoimmune disorders.

Upstream product

• 67-56-1 methanol 
• 1268524-70-4 (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate 
• 202592-23-2 (S)-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid 
• 124-41-4 sodium methylate 

Downstream Products

• 916493-58-8 methyl (S)-{4-(2'-formylbiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate 
• 916493-60-2 methyl (S)-{4-(5'-formyl-2'-methoxybiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate 
• 1349067-72-6 (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetohydrazide 

Relevant academic research and scientific papers

AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF

The present invention aims to provide a compound that: has an excellent cytotoxic action on cancer cells, excellent induction of BET protein degradation in cancer cells, and an excellent binding-inhibiting action on BET protein and acetylated histone; and is effective as an anti-cancer agent, a BET protein degradation-inducing agent, or a BET protein inhibiting agent. A compound indicated in general formula (I) or a pharmacologically acceptable salt thereof. {In the formula, each symbol is as outlined in the Description.}

HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4

Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.

A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor

A phenotypic screening of thienodiazepines derived from a hit compound found through a binding assay targeting co-stimulatory molecules on T cells and antigen presenting cells successfully led to the discovery of a thienotriazolodiazepine compound (7f) po

THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF

[Solving means] A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. [Effect]